Oncology & Cancer

ASCO: Continuing avastin with 2nd-line chemo ups survival

(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Oncology & Cancer

Drug cocktail boosts ovarian cancer survival time

A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

Oncology & Cancer

Avastin no benefit to older lung cancer patients: study

(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report.

Oncology & Cancer

Bevacizumab doesn't up overall survival in prostate cancer

(HealthDay) -- For men with metastatic castration-resistant prostate cancer (mCRPC), the addition of bevacizumab (B) to docetaxel plus prednisone (DP) is not associated with improved overall survival (OS), but does improve ...

page 7 from 12